Literature DB >> 30293898

Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.

Kathleen F O'Brien1, Sonal D Shah2, Elena Pope3, Roderic J Phillips4, Francine Blei5, Eulalia Baselga6, Maria C Garzon7, Catherine McCuaig8, Anita N Haggstrom9, Peter H Hoeger10, James R Treat11, Marissa J Perman11, Jane S Bellet12, Xavier Cubiró6, Jeffrey Poole13, Ilona J Frieden14.   

Abstract

BACKGROUND: The proliferative phase of infantile hemangiomas (IHs) is usually complete by 9 months of life. Late growth beyond age 3 years is rarely reported.
OBJECTIVE: To describe the demographic and clinic characteristics of a cohort of patients with late growth of IH, defined as growth in a patient >3 years of age.
METHODS: A multicenter, retrospective cohort study.
RESULTS: In total, 59 patients, 85% of which were female, met the inclusion criteria. The mean first episode of late growth was 4.3 (range 3-8.5) years. Head and neck location (55/59; 93%) and presence of deep hemangioma (52/59; 88%) were common characteristics. Posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities (PHACE) syndrome was noted in 20 of 38 (53%) children with segmental facial IH. Systemic therapy (corticosteroid or β-blocker) was given during infancy in 58 of 59 (98%) and 24 of 59 (41%) received systemic therapy (β-blockers) for late IH growth. LIMITATIONS: The retrospective nature and ascertainment by investigator recall are limitations of the study.
CONCLUSION: Late IH growth can occur in children after 3 years of age. Risk factors include head and neck location, segmental morphology, and involvement of deep dermal/subcutaneous tissues. Crown
Copyright © 2018. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  corticosteroid; growth hormone; infantile hemangioma; late growth; segmental morphology; β-blocker

Mesh:

Substances:

Year:  2018        PMID: 30293898     DOI: 10.1016/j.jaad.2018.07.061

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Medical Management of Infantile Hemangiomas: An Update.

Authors:  Caroline Colmant; Julie Powell
Journal:  Paediatr Drugs       Date:  2021-10-22       Impact factor: 3.022

2.  A retrospective study of parotid gland tumors at a single institution.

Authors:  Shiori Suzuki; Nobuyuki Bandoh; Takashi Goto; Akinobu Kubota; Akihiro Uemura; Michihisa Kono; Ryosuke Sato; Ryuhei Takeda; Shota Sakaue; Tomomi Yamaguchi-Isochi; Hiroshi Nishihara; Hidehiro Takei; Yasuaki Harabuchi
Journal:  Oncol Lett       Date:  2022-05-13       Impact factor: 3.111

3.  Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.

Authors:  Letícia Gaertner Mariani; Lílian Moraes Ferreira; Diego Luiz Rovaris; Renan Rangel Bonamigo; Ana Elisa Kiszewski
Journal:  An Bras Dermatol       Date:  2021-11-27       Impact factor: 1.896

Review 4.  Vascular Anomalies of the Head and Neck: A Pediatric Overview.

Authors:  Juan Putra; Alyaa Al-Ibraheemi
Journal:  Head Neck Pathol       Date:  2021-03-15

Review 5.  Childhood Vascular Tumors.

Authors:  Harriet Bagnal Hinen; Cameron C Trenor; Lara Wine Lee
Journal:  Front Pediatr       Date:  2020-10-22       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.